Table 1. Description of studies included in the meta-analysis

Author, year (ref.)	Country	Type	Design	Subjects	Cohort (No. of patients received DAAs; %SVR)	Mean age years; (Mean± SD or range)	No. of Males (%sex)	Follow-up (from EOT)	HbA1c[B] %(mmol/mol)(mean±SD)	HbA1c[A]% (mmol/mol)(mean±SD)	P value	FPG[B] (mg/dL) (Mean±SD)	FPG[A] (mg/dL) (Mean±SD)	P value	Hypoglycemic agents dosing interruption or lowering
Alem2017[9]	Egypt	cohort study	retrospective	HCV; T2DM	65 (100%) N=65	56.7±9.27	45 (69.2%)	24weeks	6.9±1.0	6.4±1.0	p<0.001	113±30.4	103±17.8	p=0.005	NA
Dawood2017[10]	Egypt	cohort study	retrospective	HCV; T2DM	400 (94.5%) N=378; N*=60	53.04 (no SD or range)	180 (47.62%)	3months	8.1±0.5	7.5±0.5	NA	183.5±27.4	146.7±30.0	NA	yes
Hum2017[14]	USA	cohort study	retrospective	HCV; T2DM	2180 (100%) N=2180 N*=255	62.2±5.2	2374 (97.5%)	from 3 to 15 months	7.20±1.5	6.82±1.3	p＝0.03	NA	NA	NA	yes
Stine2017[23]	USA	cohort study	retrospective	HCV; T2DM	26 (100%) N=26	56±9.5	20 (76.9%)	12weeks	7.4±2.0	7.1±1.9	p=0.268	NA	NA	NA	NO
Ciancio2018[8]	Italy	cohort study	prospective	HCV; T2DM	101 (100%) N=101 N*=21	61.39±10.92	71 (70.3%);	12weeks	6.9±3.6	6.4±3.6	p<0.001	152.4±56.4	134.3±41.3	p=0.002	yes
Boraie2019[32]	Egypt	cohort study	prospective	HCV; T2DM	120 (96.7%) N=116	52.1±8.4	NA	12weeks	7.6±0.7	6.7±0.8	p=0.0001	121±6.7	112.6±6.6	NA	yes
Carnovale2019[33]	Italy	cohort study	retrospective	HCV; T2DM	93 (100%) N (HbA1c) =26; N(FPG)=90	64±11	72 (73%)	12weeks	7.6±3.6	6.7±3.6	p=0.0039	166.9±50.6	149.9±49.5	p=0.0378	NA

Author, year (ref.)	Country	Type	Design	Subjects	Cohort (No. of patients received DAAs; %SVR)	Mean age years; (Mean± SD or range)	No. of Males (%sex)	Follow-up (from EOT)	HbA1c[B] %(mmol/mol)(mean±SD)	HbA1c[A]% (mmol/mol)(mean±SD)	P value	FPG[B] (mg/dL) (Mean±SD)	FPG[A] (mg/dL) (Mean±SD)	P value	Hypoglycemic agents dosing interruption or lowering
Gilad2019[13]	USA	cohort study	retrospective	HCV; T2DM	123 (99.2%) N=122	60 (56-64)	87 (71.3%)	1.5years	8.4±1.9 (12weeks)	7.8±1.7 (12weeks)	p<0.001	NA	NA	NA	NA
Lanini2019[19]	Italy	cohort study	retrospective	HCV; T2DM	54 (100%) N=54	NA	NA	6-18months	NA	NA	NA	146.7±8.9	128.0±6.5	NA	NA
Mada2020[36]	USA	cohort study	retrospective	HCV; T2DM	59 (93%) N=55; N*=59	59.2±0.8;	26 (44.1%)	6months	7.7±0.7	6.7±0.6	p<0.0001	NA	NA	NA	no
Wong2020[37]	USA	cohort study	retrospective	HCV; T2DM	937 (100%); N=937; N*=59	61.3±8.24;	623 (66.5%);	12months	7.5±1.45	7.1±1.25	p<0.0001	NA	NA	NA	NA
Zied2020[38]	Egypt	cohort study	prospective	HCV; T2DM	100 (92%) N=92	52.7±10.45	NA	12weeks	7.95±1.09	7.54±0.8	p=0.003	219.06±111.36	112.37±20.66	p=0.009	NA
Hussein2020[35]	Egypt	cohort study	prospective	HCV; T2DM	128 (100%) N=128	54.7±8.3	72 (56.25%)	12weeks	7.4±0.81	6.7±0.82	p<0.001	NA	NA	NA	NA
Abdo2020[34]	Egypt	cohort study	retrospective	HCV; T2DM	114 (86.0%) N=98	51.54±6.91	44 (44.9%)	12weeks	7.1±1.4	6.65±1.1	p<0.0001	110.82±25.1	101.89±15.7	p=0.0002	NA
Takahashi2020[20]	Japan	cohort study	retrospective	HCV; T2DM	55 (100%) N=55	NA	NA	12weeks	7.3±0.8	7.0±0.8	p<0.05	173.7±78.8	161.3±72.2	NA	yes

Author, year (ref.)	Country	Type	Design	Subjects	Cohort (No. of patients received DAAs; %SVR)	Mean age years; (Mean± SD or range)	No. of Males (%sex)	Follow-up (from EOT)	HbA1c[B] %(mmol/mol)(mean±SD)	HbA1c[A]% (mmol/mol)(mean±SD)	P value	FPG[B] (mg/dL) (Mean±SD)	FPG[A] (mg/dL) (Mean±SD)	P value	Hypoglycemic agents dosing interruption or lowering
Cacciola2021 [21]	Italy	cohort study	prospective	HCV; T2DM	182 (100%) N=70*	69 (41-91)	34 (48.6%)	120weeks	7.1±1.4	6.5±1.1	p<0.001	134±38.8	121±30	p=0.05	yes

Abbreviation: [B]: before DAA; [A]: after SVR; EOT: end of treatment; NA: not available; N: number of patients available in the meta-analysis. N*：number of patients in control group (non-SVR group). P-value represents comparison between the two groups in front of it.